Michael C. Wei
YOU?
Author Swipe
Disruption of acyl-acyl carrier protein (acyl-ACP) synthetase in cyanobacteria impairs lipid remodeling as revealed by acyl-ACP measurements Open
Free fatty acid (FFA) production in bacteria is a key target for metabolic engineering. The knockout of the acyl-ACP synthetase (AAS) prevents reincorporation of FFA into the fatty acid biosynthetic cycle and is widely used to enhance thei…
View article: Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy Open
Background: HRQoL is often impaired in pts with R/R LBCL (Abramson et al. ASH 2021). SUNMO (NCT05171647), a randomized Phase III study, compared Mosun-Pola vs R-GemOx in pts with R/R LBCL. Mosun-Pola significantly improved overall response…
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma Open
Background: A prior analysis of mosunetuzumab (Mosun) SC, a CD20xCD3 T-cell-engaging bispecific antibody, with polatuzumab vedotin (Pola; M-Pola), an anti-CD79b monoclonal antibody, in a Phase Ib/II study (NCT03671018) showed promising dur…
Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL Open
The recent surge in T‐cell‐engaging and chimeric antigen receptor (CAR) T‐cell therapies is changing the landscape of cancer therapy. Cytokine release syndrome (CRS) is a systemic inflammatory response syndrome that is a well‐known complic…
View article: Persistent fatty acid catabolism during plant oil synthesis
Persistent fatty acid catabolism during plant oil synthesis Open
Plant lipids are an essential energy source for diets and are a sustainable alternative to petroleum-based fuels and feedstocks. Fatty acid breakdown during seed germination is crucial for seedling establishment but unexpected during seed …
View article: Persistent fatty acid catabolism during plant oil synthesis
Persistent fatty acid catabolism during plant oil synthesis Open
SUMMARY Plant lipids are an essential energy source for diets and are a sustainable alternative to petroleum-based fuels and feed stocks. Fatty acid breakdown during seed germination is crucial for seedling establishment but unexpected dur…
View article: Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Open
This phase 2 study evaluated mosunetuzumab plus cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (Pola-M-CHP) vs Pola-rituximab (R)-CHP for first-line treatment of diffuse large B-cell lymphoma. Patients were randomized 2…
View article: Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas Open
Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor (CAR)–modified T cells (CAR-T). The optimal timing of BsAbs and bioma…
Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II Open
Background: Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody approved by the FDA and EMA for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior lines of therapy by intravenous (IV) administration. In a…
Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab Open
Background: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody that is being evaluated in patients with select B-cell non-Hodgkin lymphoma (B-NHL) histologies in a Phase I/II clinical trial (NCT02500407). Mosunetuzumab is appr…
View article: A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Open
Background: The ongoing Phase Ib/II study (NCT03671018) evaluates mosunetuzumab (Mosun) plus polatuzumab vedotin (Pola; M-Pola) in pts with R/R LBCL. The Phase II single-arm expansion cohort showed a manageable safety profile and highly du…
Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study Open
Background: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved by the FDA and EMA for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior lines of therapy. In a pivotal Phase II study (N…
Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma Open
Background: New treatment options are needed for patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those with progressive disease (PD) after Bruton's tyrosine kinase inhibitor (BTKi) therapy. Mosunetuzuma…
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies Open
Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patient…
View article: Automated Lugano Metabolic Response Assessment in <sup>18</sup> F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on <sup>18</sup> F-Fluorodeoxyglucose–Positron Emission Tomography
Automated Lugano Metabolic Response Assessment in <sup>18</sup> F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on <sup>18</sup> F-Fluorodeoxyglucose–Positron Emission Tomography Open
PURPOSE Artificial intelligence can reduce the time used by physicians on radiological assessments. For 18 F-fluorodeoxyglucose–avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic. METHODS Here, we…
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas Open
CD20 is an established therapeutic target in B-cell malignancies. The CD20 × CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of re…
View article: Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma Open
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstr…
View article: Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL) Open
Introduction: Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. Clinical data from GO29781 (NCT02500407), a Phase I/II, open-label, multicenter dose-escalation an…
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy Open
A comparison of clinical outcomes in the third or subsequent line (3 L+) of systemic therapy between a real-world data (RWD) external control cohort and a mosunetuzumab single-arm clinical trial cohort is presented. Data for 3 L + patients…
View article: Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study Open
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirec…
P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. In a pivotal Phase II study (NCT…
BBCA-LEDGER: High Throughput Consensus meets Low Latency Open
This paper presents BBCA-LEDGER, a Byzantine log replication technology for partially synchronous networks enabling blocks to be broadcast in parallel, such that each broadcast is finalized independently and instantaneously into an individ…
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma Open
As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines…
View article: Supplementary Table S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Supplementary Table S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer Open
Study disposition
View article: Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Purpose:Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helic…